These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 34690091)

  • 1. Clinical Characteristics, Prognosis, and Treatment Strategies of TP53 Mutations in Myelodysplastic Syndromes.
    Fang K; Qi J; Zhou M; Zhang Z; Han Y
    Clin Lymphoma Myeloma Leuk; 2022 Apr; 22(4):224-235. PubMed ID: 34690091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
    Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
    Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic impact of variant allele frequency (VAF) in TP53 mutant patients with MDS: A systematic review and meta-analysis.
    Deng J; Wu X; Ling Y; Liu X; Zheng X; Ye W; Gong Y
    Eur J Haematol; 2020 Nov; 105(5):524-539. PubMed ID: 32621334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents.
    Takahashi K; Patel K; Bueso-Ramos C; Zhang J; Gumbs C; Jabbour E; Kadia T; Andreff M; Konopleva M; DiNardo C; Daver N; Cortes J; Estrov Z; Futreal A; Kantarjian H; Garcia-Manero G
    Oncotarget; 2016 Mar; 7(12):14172-87. PubMed ID: 26871476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role Of TP53 mutations in predicting the clinical efficacy of hypomethylating therapy in patients with myelodysplastic syndrome and related neoplasms: a systematic review and meta-analysis.
    Cai L; Zhao X; Ai L; Wang H
    Clin Exp Med; 2020 Aug; 20(3):361-371. PubMed ID: 32613269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes and characteristics of patients with
    Zhang L; Chen K; Li Y; Chen Q; Shi W; Ji T; Tao H; He Z; Wang C; Yu L
    Hematology; 2023 Dec; 28(1):2181773. PubMed ID: 36892252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical characteristics and prognosis of patients with myelodysplastic syndrome with a bone marrow nucleated erythroid cell proportion of greater than or equal to 50].
    Zeng YP; Li B; Qin TJ; Xu ZF; Qu SJ; Pan LJ; Gao QY; Jiao M; Wu JY; Wang HJ; Li CW; Ja YJ; Sun Q; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2024 Jul; 45(7):651-659. PubMed ID: 39231769
    [No Abstract]   [Full Text] [Related]  

  • 8. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation.
    Bejar R; Stevenson KE; Caughey B; Lindsley RC; Mar BG; Stojanov P; Getz G; Steensma DP; Ritz J; Soiffer R; Antin JH; Alyea E; Armand P; Ho V; Koreth J; Neuberg D; Cutler CS; Ebert BL
    J Clin Oncol; 2014 Sep; 32(25):2691-8. PubMed ID: 25092778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
    Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
    Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Epigenomic Hypermethylation at TP53 on Allogeneic Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndromes.
    Wang W; Auer P; Zhang T; Spellman S; Carlson KS; Nazha A; Bolon YT; Saber W
    Transplant Cell Ther; 2021 Aug; 27(8):659.e1-659.e6. PubMed ID: 33992829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting TP53 Mutations in Myelodysplastic Syndromes.
    Hunter AM; Sallman DA
    Hematol Oncol Clin North Am; 2020 Apr; 34(2):421-440. PubMed ID: 32089220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of TP53 mutations in low-grade myelodysplastic syndromes and myelodysplastic syndromes with a non-complex karyotype.
    Wang W; Routbort MJ; Tang Z; Ok CY; Patel KP; Daver N; Garcia-Manero G; Medeiros LJ; Wang SA
    Eur J Haematol; 2017 Dec; 99(6):536-543. PubMed ID: 28926144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes.
    Montalban-Bravo G; Kanagal-Shamanna R; Benton CB; Class CA; Chien KS; Sasaki K; Naqvi K; Alvarado Y; Kadia TM; Ravandi F; Daver N; Takahashi K; Jabbour E; Borthakur G; Pemmaraju N; Konopleva M; Soltysiak KA; Pierce SR; Bueso-Ramos CE; Patel KP; Kantarjian H; Garcia-Manero G
    Blood Adv; 2020 Feb; 4(3):482-495. PubMed ID: 32027746
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Ball S; Loghavi S; Zeidan AM
    Leuk Lymphoma; 2023 Mar; 64(3):540-550. PubMed ID: 36323304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with
    Ciurea SO; Chilkulwar A; Saliba RM; Chen J; Rondon G; Patel KP; Khogeer H; Shah AR; Randolph BV; Perez JMR; Popat U; Hosing CM; Bashir Q; Mehta R; Al-Atrash G; Im J; Khouri IF; Kebriaei P; Champlin RE
    Blood; 2018 Jun; 131(26):2989-2992. PubMed ID: 29769261
    [No Abstract]   [Full Text] [Related]  

  • 16. Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study.
    Versluis J; Saber W; Tsai HK; Gibson CJ; Dillon LW; Mishra A; McGuirk J; Maziarz RT; Westervelt P; Hegde P; Mukherjee D; Martens MJ; Logan B; Horowitz M; Hourigan CS; Nakamura R; Cutler C; Lindsley RC;
    J Clin Oncol; 2023 Oct; 41(28):4497-4510. PubMed ID: 37607457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular characterization and prognosis of mutant TP53 acute myeloid leukemia and myelodysplastic syndrome with excess blasts.
    Shen K; Hu DY; Zhang ZB; Guo YS; Zhang FH; Chen SN
    Int J Lab Hematol; 2023 Jun; 45(3):344-352. PubMed ID: 36860196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation.
    Yoshizato T; Nannya Y; Atsuta Y; Shiozawa Y; Iijima-Yamashita Y; Yoshida K; Shiraishi Y; Suzuki H; Nagata Y; Sato Y; Kakiuchi N; Matsuo K; Onizuka M; Kataoka K; Chiba K; Tanaka H; Ueno H; Nakagawa MM; Przychodzen B; Haferlach C; Kern W; Aoki K; Itonaga H; Kanda Y; Sekeres MA; Maciejewski JP; Haferlach T; Miyazaki Y; Horibe K; Sanada M; Miyano S; Makishima H; Ogawa S
    Blood; 2017 Apr; 129(17):2347-2358. PubMed ID: 28223278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations.
    Dutta S; Moritz J; Pregartner G; Thallinger GG; Brandstätter I; Lind K; Rezania S; Lyssy F; Reinisch A; Zebisch A; Berghold A; Wölfler A; Sill H
    Ann Hematol; 2022 Apr; 101(4):837-846. PubMed ID: 35083527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes with allogeneic hematopoietic stem cell transplantation in TP53-mutated myelodysplastic syndrome: A systematic review and meta-analysis.
    Shahzad M; Iqbal Q; Tariq E; Ammad-Ud-Din M; Butt A; Mushtaq AH; Ali F; Chaudhary SG; Anwar I; Gonzalez-Lugo JD; Abdelhakim H; Ahmed N; Hematti P; Singh AK; McGuirk JP; Mushtaq MU
    Crit Rev Oncol Hematol; 2024 Apr; 196():104310. PubMed ID: 38423375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.